Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-02-09. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientchemotherapycellpatients mustcancer
  Phrases that lowered it: relapsedrefractoryhcvhepatitis virusrna
• Sponsor's past termination rate: 11.7% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 109 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 298 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Collaborators: 2 (lowers risk) · Design
• Drug's FAERS reports before start: 144097 (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Maximum age: 70 (lowers risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports with a death: 22.6% (raises risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 5 (lowers risk) · Drug's FDA history
• Minimum age: 16 (raises risk) · Who can join
• Responsible party: sponsor (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 28662 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) NCT04833114 · started 2021 · scored riskier than 69% of active trials completed
• Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy NCT03422523 · started 2018 · scored riskier than 68% of active trials terminated
• Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide NCT01458366 · started 2011 · scored riskier than 96% of active trials completed
• Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients NCT01994850 · started 2013 · scored riskier than 95% of active trials completed
• A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab. NCT01289223 · started 2011 · scored riskier than 76% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.